Table 1. Baseline characteristics of patients with sickle cell disease that underwent hematopoietic stem cell transplantation (HSCT) vs. continued standard care.
| Clinical Variable | Non-HSCT(n = 67) | HSCT(n = 16) | P Value |
|---|---|---|---|
| Age (years) | 34 (23–44) | 33 (24–34) | 0.2 |
| Male (%): Female (%) | 34%: 66% | 56%: 44% | 0.1 |
| Hb SS Genotype | 54 (81%) | 15 (94%) | 0.4 |
| Insurance Type | Medicaid: 37 (55%) Medicare: 19 (28%) Private: 11 (16%) |
Medicaid: 5 (31%) Medicare: 8 (50%) Private: 3 (19%) |
0.2 |
| Sickle cell disease-related therapy | Hydroxyurea: 40 (60%) Chronic RBC transfusions: 15 (22%) |
Hydroxyurea: 10 (63%) Chronic RBC transfusions: 5 (31%) |
0.8 0.5 |
| HSCT eligibility criteria | ≥ 3 VOC/year: 61 (91%) ≥ 2 ACS/lifetime: 52 (78%) Stroke: 17 (25%) |
≥ 3 VOC/year: 14 (88%) ≥ 2 ACS/lifetime: 12 (75%) Stroke: 4 (25%) |
0.7 0.8 1.0 |
RBC, red blood cell; VOC, vaso-occlusive crisis; ACS, acute chest syndrome
Median (interquartile range) provided